XKRX
002390
Market cap83mUSD
Oct 08, Last price
8,600.00KRW
1D
-0.58%
1Q
9.00%
Jan 2017
-67.24%
Name
Handok Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products. In addition, the company engages in real estate leasing. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is headquartered in Seoul, South Korea.
Key people
Jin Gi Baek
Co-Chief Executive Officer, Director · since 2020
Hyeon Cheol Lee
Chief Financial Officer, Managing Director · since 2019
Ju Yeon Yoon
Vice President · since 2024
Seung Ho Baek
Managing Director · since 2020
Yun Mi Kim
Managing Director · since 2023
Eun Cheon Lee
Managing Director · since 2023
Yeong Hui Gwak
Assistant Managing Director · since 2019
Eun Hui Huh
Assistant Managing Director · since 2020
Bok Jin Hyun
Assistant Managing Director · since 2022
Mi Gyeong Jang
Assistant Managing Director
Hyeon Suk Kim
Assistant Managing Director · since 2019
Eun Ju Kim
Assistant Managing Director · since 2014
Yin Gyeong Lee
Assistant Managing Director · since 2023
Jong Pyo Lee
Assistant Managing Director · since 2021
Pil Jong Oh
Assistant Managing Director · since 2024
Yeong Kim
Managing Director · since 2020
Mi Yeon Kim
President, Chief Operating Officer, Director · since 2024
Dong Han Kim
Managing Director · since 2024
Jin Yeop Jung
Non-Executive Independent Director · since 2021
Non-Executive Independent Director · since 2020
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||